US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
LT1962805T
(lt)
|
2005-12-08 |
2016-10-25 |
Insmed Incorporated |
Antiinfekcinės lipidų pagrindo kompozicijos, skirtos plaučių infekcijų gydymui
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
DK2180787T3
(da)
|
2007-08-01 |
2014-02-03 |
Univ Pittsburgh |
Nitrooliesyremodulering af type ii-diabetes
|
EP2238251B1
(en)
|
2007-12-27 |
2015-02-11 |
Protiva Biotherapeutics Inc. |
Silencing of polo-like kinase expression using interfering rna
|
NZ588583A
(en)
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
JP2011519373A
(ja)
|
2008-05-01 |
2011-07-07 |
コンプレクザ インコーポレイテッド |
ビニル置換脂肪酸
|
US20140024713A1
(en)
|
2008-06-19 |
2014-01-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
US8686038B2
(en)
|
2008-06-19 |
2014-04-01 |
The Univsersity of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
CN106834291B
(zh)
*
|
2008-10-20 |
2020-09-29 |
阿尔尼拉姆医药品有限公司 |
抑制运甲状腺素蛋白表达的组合物和方法
|
AU2015249072C1
(en)
*
|
2008-10-20 |
2022-10-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
CN104910025B
(zh)
|
2008-11-07 |
2019-07-16 |
麻省理工学院 |
氨基醇类脂质和其用途
|
EP3699172A3
(en)
|
2008-11-10 |
2020-11-18 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
US8722082B2
(en)
|
2008-11-10 |
2014-05-13 |
Tekmira Pharmaceuticals Corporation |
Lipids and compositions for the delivery of therapeutics
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
US20120101148A1
(en)
*
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
WO2010105209A1
(en)
*
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
CA3045126A1
(en)
*
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
US8158601B2
(en)
|
2009-06-10 |
2012-04-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulation
|
NZ597504A
(en)
*
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
CA2767129C
(en)
*
|
2009-07-01 |
2015-01-06 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein b
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
CA2769624C
(en)
|
2009-07-31 |
2018-09-11 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Electrophilic fatty acid derivatives as anti-inflammatory agents
|
US9181295B2
(en)
|
2009-08-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
Cationic lipids with various head groups for oligonucleotide delivery
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
US8686167B2
(en)
|
2009-10-02 |
2014-04-01 |
Complexa, Inc. |
Heteroatom containing substituted fatty acids
|
US9101643B2
(en)
|
2009-11-03 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
|
ME03091B
(me)
|
2009-12-01 |
2019-01-20 |
Translate Bio Inc |
Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima
|
WO2011088309A1
(en)
*
|
2010-01-14 |
2011-07-21 |
Regulus Therapeutics Inc. |
Microrna compositions and methods
|
EP2526113B1
(en)
|
2010-01-22 |
2016-08-10 |
Sirna Therapeutics, Inc. |
Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
|
EP2558074B1
(en)
|
2010-04-08 |
2018-06-06 |
The Trustees of Princeton University |
Preparation of lipid nanoparticles
|
JP5902617B2
(ja)
*
|
2010-04-28 |
2016-04-13 |
協和発酵キリン株式会社 |
カチオン性脂質
|
JP5902616B2
(ja)
*
|
2010-04-28 |
2016-04-13 |
協和発酵キリン株式会社 |
カチオン性脂質
|
WO2011141705A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
US8865675B2
(en)
|
2010-05-12 |
2014-10-21 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein B
|
JP2013531634A
(ja)
|
2010-05-24 |
2013-08-08 |
メルク・シャープ・エンド・ドーム・コーポレイション |
オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
|
CN103096875B
(zh)
|
2010-06-03 |
2016-08-17 |
阿尔尼拉姆医药品有限公司 |
用于递送活性剂的生物可降解脂质
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
BR112013000392B8
(pt)
|
2010-07-06 |
2022-10-04 |
Novartis Ag |
Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso
|
LT3243526T
(lt)
|
2010-07-06 |
2020-02-10 |
Glaxosmithkline Biologicals S.A. |
Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
|
SI2590626T1
(sl)
|
2010-07-06 |
2016-01-29 |
Glaxosmithkline Biologicals S.A. |
Liposomi z lipidi, ki imajo koristno pKa vrednost, za dostavo RNA
|
CA2804492A1
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation of large mammals with low doses of rna
|
WO2012016184A2
(en)
*
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
KR102072631B1
(ko)
|
2010-08-17 |
2020-02-03 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제
|
US9233997B2
(en)
|
2010-08-26 |
2016-01-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
|
WO2012027675A2
(en)
|
2010-08-26 |
2012-03-01 |
Massachusetts Institute Of Technology |
Poly(beta-amino alcohols), their preparation, and uses thereof
|
JP5911870B2
(ja)
|
2010-08-31 |
2016-04-27 |
ノバルティス アーゲー |
免疫原をコードするrnaの送達のためのpeg化リポソーム
|
EP3406730B1
(en)
|
2010-08-31 |
2022-02-23 |
Sirna Therapeutics, Inc. |
Novel single chemical entities and methods for delivery of oligonucleotides
|
WO2012031205A2
(en)
|
2010-09-03 |
2012-03-08 |
The Brigham And Women's Hospital, Inc. |
Lipid-polymer hybrid particles
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
JP5961170B2
(ja)
|
2010-09-20 |
2016-08-02 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
オリゴヌクレオチドの送達のための新規な低分子量カチオン性脂質
|
EP2621480B1
(en)
|
2010-09-30 |
2018-08-15 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
ES2862955T3
(es)
|
2010-10-01 |
2021-10-08 |
Modernatx Inc |
Acidos nucleicos manipulados y métodos de uso de los mismos
|
US20140030292A1
(en)
|
2010-10-11 |
2014-01-30 |
Novartis Ag |
Antigen delivery platforms
|
US9029590B2
(en)
|
2010-10-21 |
2015-05-12 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
WO2012061259A2
(en)
|
2010-11-05 |
2012-05-10 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
PL2691443T3
(pl)
|
2011-03-28 |
2021-08-30 |
Massachusetts Institute Of Technology |
Sprzężone lipomery i ich zastosowania
|
US8710200B2
(en)
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
EP3354644A1
(en)
|
2011-06-08 |
2018-08-01 |
Translate Bio, Inc. |
Cleavable lipids
|
EP2717893B1
(en)
*
|
2011-06-08 |
2019-05-08 |
Translate Bio, Inc. |
Lipid nanoparticle compositions and methods for mrna delivery
|
US20140141070A1
(en)
|
2011-07-06 |
2014-05-22 |
Andrew Geall |
Liposomes having useful n:p ratio for delivery of rna molecules
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
EP2744491B1
(en)
|
2011-08-19 |
2020-07-29 |
The University of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
US9126966B2
(en)
*
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2013052523A1
(en)
|
2011-10-03 |
2013-04-11 |
modeRNA Therapeutics |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
US9271952B2
(en)
*
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
EA201891809A1
(ru)
|
2011-10-27 |
2019-05-31 |
Массачусетс Инститьют Оф Текнолоджи |
Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство
|
PT3301177T
(pt)
*
|
2011-11-18 |
2020-06-29 |
Alnylam Pharmaceuticals Inc |
Agentes de arni, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
DK3988537T1
(da)
|
2011-12-07 |
2022-05-23 |
Alnylam Pharmaceuticals Inc |
Bionedbrydelige lipider til afgivelse af aktive midler
|
CA3170051A1
(en)
*
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
US20130197205A1
(en)
|
2012-01-27 |
2013-08-01 |
Hoffmann-La Roche Inc. |
Chitosan covalently linked with small molecule integrin antagonist for targeted delivery
|
WO2013110578A1
(en)
|
2012-01-27 |
2013-08-01 |
F. Hoffmann-La Roche Ag |
Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3
|
DK2806897T3
(en)
|
2012-01-27 |
2017-10-16 |
Hoffmann La Roche |
INTEGRIN ANAGONIST CONJUGATES FOR TARGETED RELEASE TO LFA-1 EXPRESSING CELLS
|
JP6159740B2
(ja)
|
2012-01-27 |
2017-07-05 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Vla−4を発現する細胞への標的化送達のためのインテグリンアンタゴニスト結合体
|
KR20220045089A
(ko)
|
2012-02-24 |
2022-04-12 |
아뷰터스 바이오파마 코포레이션 |
트리알킬 양이온성 지질 및 그의 사용 방법
|
CN102600173B
(zh)
*
|
2012-03-02 |
2013-05-29 |
海南美兰史克制药有限公司 |
氨氯地平/贝那普利药物组合物脂质体固体制剂
|
US10322089B2
(en)
*
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
ES2762873T3
(es)
|
2012-03-29 |
2020-05-26 |
Translate Bio Inc |
Lípidos catiónicos ionizables
|
ES2858523T3
(es)
|
2012-03-29 |
2021-09-30 |
Translate Bio Inc |
Nanopartículas neutras derivadas de lípidos
|
AU2013243949A1
(en)
*
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
EP2833920A2
(en)
|
2012-04-02 |
2015-02-11 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
JP6232416B2
(ja)
|
2012-04-19 |
2017-11-15 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
オリゴヌクレオチド送達のための、新規なジエステルおよびトリエステルベースの低分子量、生分解性カチオン性脂質
|
EP2859102A4
(en)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
|
EP3884949A1
(en)
|
2012-06-08 |
2021-09-29 |
Translate Bio, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
US9415109B2
(en)
|
2012-07-06 |
2016-08-16 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
TW201726599A
(zh)
|
2012-07-06 |
2017-08-01 |
協和醱酵麒麟有限公司 |
陽離子性脂質
|
CA2884870C
(en)
|
2012-08-13 |
2022-03-29 |
Massachusetts Institute Of Technology |
Amine-containing lipidoids and uses thereof
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
RU2675859C2
(ru)
|
2012-11-29 |
2018-12-25 |
Инсмед Инкорпорейтед |
Стабилизированные составы ванкомицина
|
EP3628335B1
(en)
|
2012-12-07 |
2023-11-08 |
Translate Bio, Inc. |
Lipidic nanoparticles for mrna delivery in the lungs
|
WO2014152966A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Methods for purification of messenger rna
|
CN105142676B
(zh)
|
2013-03-14 |
2022-06-28 |
夏尔人类遗传性治疗公司 |
Cftr mrna组合物以及相关方法和用途
|
CA2903880A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
US8980864B2
(en)
*
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP3757570B1
(en)
|
2013-03-15 |
2023-10-11 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
WO2014179562A1
(en)
|
2013-05-01 |
2014-11-06 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
EA201690588A1
(ru)
|
2013-10-22 |
2016-09-30 |
Шир Хьюман Дженетик Терапис, Инк. |
Доставка мрнк в цнс и ее применение
|
CN106413811A
(zh)
|
2013-10-22 |
2017-02-15 |
夏尔人类遗传性治疗公司 |
精氨基琥珀酸合成酶缺乏症的mrna疗法
|
MX2016005239A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
|
KR101988552B1
(ko)
|
2013-10-22 |
2019-09-25 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 전달을 위한 지질 제형
|
KR102252561B1
(ko)
|
2013-11-22 |
2021-05-20 |
미나 테라퓨틱스 리미티드 |
C/ebp 알파 짧은 활성화 rna 조성물 및 사용 방법
|
CA2932122C
(en)
|
2013-12-03 |
2022-04-19 |
Northwestern University |
Liposomal particles, methods of making same and uses thereof
|
TWI648067B
(zh)
*
|
2014-01-09 |
2019-01-21 |
日商衛材R&D企管股份有限公司 |
陽離子性脂質
|
EP3556353A3
(en)
|
2014-02-25 |
2020-03-18 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
EP3122878B1
(en)
|
2014-03-24 |
2018-10-24 |
Translate Bio, Inc. |
Mrna therapy for the treatment of ocular diseases
|
SG11201608798YA
(en)
|
2014-04-23 |
2016-11-29 |
Modernatx Inc |
Nucleic acid vaccines
|
EA201691696A1
(ru)
|
2014-04-25 |
2017-03-31 |
Шир Хьюман Дженетик Терапис, Инк. |
Способы очистки матричной рнк
|
EP3142643B1
(en)
|
2014-05-15 |
2019-07-10 |
Insmed Incorporated |
Methods for treating pulmonary non-tuberculous mycobacterial infections
|
CN105085295A
(zh)
*
|
2014-05-23 |
2015-11-25 |
上海交通大学 |
氨甲环酸的两亲性衍生物及其用途
|
CN105085292B
(zh)
*
|
2014-05-23 |
2017-12-15 |
上海交通大学 |
3‑((2‑(二甲氨基)乙烷基)(甲基)氨基)丙酸的两亲性衍生物及其用途
|
ES2750686T3
(es)
|
2014-05-30 |
2020-03-26 |
Translate Bio Inc |
Lípidos biodegradables para la administración de ácidos nucleicos
|
CN106535876B
(zh)
|
2014-06-04 |
2020-09-11 |
埃克西奎雷股份有限公司 |
免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用
|
ES2964588T3
(es)
|
2014-06-24 |
2024-04-08 |
Translate Bio Inc |
Composiciones enriquecidas estereoquímicamente para la administración de ácidos nucleicos
|
HRP20221536T1
(hr)
|
2014-06-25 |
2023-02-17 |
Acuitas Therapeutics Inc. |
Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
|
CA2959358C
(en)
|
2014-06-30 |
2022-07-26 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
CN106456547B
(zh)
|
2014-07-02 |
2021-11-12 |
川斯勒佰尔公司 |
信使rna的包封
|
EP3164379A1
(en)
|
2014-07-02 |
2017-05-10 |
Massachusetts Institute of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
GB201414464D0
(en)
|
2014-08-14 |
2014-10-01 |
Technion Res & Dev Foundation |
Compositions and methods for therapeutics prescreening
|
KR102631505B1
(ko)
|
2014-08-29 |
2024-02-01 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
|
WO2016090262A1
(en)
|
2014-12-05 |
2016-06-09 |
Shire Human Genetic Therapies, Inc. |
Messenger rna therapy for treatment of articular disease
|
AU2016233135B2
(en)
|
2015-03-19 |
2021-07-08 |
Translate Bio, Inc. |
mRNA therapy for pompe disease
|
TW201642837A
(zh)
|
2015-03-24 |
2016-12-16 |
Kyowa Hakko Kirin Co Ltd |
含有核酸之脂質奈米粒子
|
EP3283125B1
(en)
|
2015-04-17 |
2021-12-29 |
CureVac Real Estate GmbH |
Lyophilization of rna
|
SG11201708679YA
(en)
|
2015-05-06 |
2017-11-29 |
Benitec Biopharma Ltd |
Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
|
CN104803863B
(zh)
*
|
2015-05-08 |
2016-07-20 |
厦门成坤生物技术有限公司 |
阳离子类脂化合物及其制备方法
|
CN107530448A
(zh)
|
2015-05-20 |
2018-01-02 |
库瑞瓦格股份公司 |
包含长链rna的干粉组合物
|
SG11201708540VA
(en)
|
2015-05-20 |
2017-12-28 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
HRP20230494T1
(hr)
|
2015-06-19 |
2023-08-04 |
Massachusetts Institute Of Technology |
Alkenil supstituirani 2,5-piperazindioni i njihova upotreba u pripravcima za isporuku sredstva subjektu ili stanici
|
US10221127B2
(en)
|
2015-06-29 |
2019-03-05 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
AU2016289856B2
(en)
|
2015-07-07 |
2020-11-26 |
H. Lundbeck A/S |
PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
|
CA2989884A1
(en)
*
|
2015-07-09 |
2017-01-12 |
Insmed Incorporated |
Compositions and methods for treating lung diseases and lung injury
|
US11007260B2
(en)
|
2015-07-21 |
2021-05-18 |
Modernatx, Inc. |
Infectious disease vaccines
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
ES2842300T3
(es)
|
2015-07-31 |
2021-07-13 |
Alnylam Pharmaceuticals Inc |
Composiciones de ARNi de transtiretina (TTR) y métodos para su uso para el tratamiento o la prevención de enfermedades asociadas con TTR
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
AU2016312530A1
(en)
|
2015-08-24 |
2018-03-01 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
HRP20220156T1
(hr)
|
2015-09-17 |
2022-04-15 |
Modernatx, Inc. |
Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
|
SG10201913953UA
(en)
|
2015-10-02 |
2020-03-30 |
Complexa Inc |
Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
|
WO2017062513A1
(en)
|
2015-10-05 |
2017-04-13 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
US10144942B2
(en)
|
2015-10-14 |
2018-12-04 |
Translate Bio, Inc. |
Modification of RNA-related enzymes for enhanced production
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
TN2018000152A1
(en)
|
2015-10-22 |
2019-10-04 |
Modernatx Inc |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
EP4011451A1
(en)
|
2015-10-22 |
2022-06-15 |
ModernaTX, Inc. |
Metapneumovirus mrna vaccines
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
HRP20220652T1
(hr)
|
2015-12-10 |
2022-06-24 |
Modernatx, Inc. |
Pripravci i postupci unosa terapijskih sredstava
|
CN106883158B
(zh)
*
|
2015-12-15 |
2019-08-23 |
中国科学院广州生物医药与健康研究院 |
生物可降解的氨基脂质类化合物及其制备方法和应用
|
DK3394030T3
(da)
|
2015-12-22 |
2022-03-28 |
Modernatx Inc |
Forbindelser og sammensætninger til intracellulær afgivelse af midler
|
CA3009131A1
(en)
|
2015-12-25 |
2017-06-29 |
Kyowa Hakko Kirin Co., Ltd. |
Compounds as cationic lipids and their use in nucleic acid delivery compositions
|
CN105622473B
(zh)
*
|
2016-02-06 |
2017-07-25 |
吴国球 |
一种阳离子氨基脂质及其合成方法和用途
|
US20190046638A1
(en)
|
2016-04-01 |
2019-02-14 |
Checkmate Pharmaceuticals, Inc. |
Fc RECEPTOR-MEDIATED DRUG DELIVERY
|
WO2017177169A1
(en)
|
2016-04-08 |
2017-10-12 |
Rana Therapeutics, Inc. |
Multimeric coding nucleic acid and uses thereof
|
AU2017250017B2
(en)
|
2016-04-14 |
2022-12-22 |
Benitec IP Holdings Inc. |
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
|
EP3452598A4
(en)
|
2016-05-06 |
2020-04-29 |
Exicure, Inc. |
LIPOSOMAL SPHERIC NUCLEIC ACID (SNA) CONSTRUCTS WITH ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC KNOCKDOWN OF INTERLEUKIN-17 RECEPTOR MRNA
|
JP7312552B2
(ja)
*
|
2016-05-16 |
2023-07-21 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
ナノ粒子としてのtRNA送達用組成物およびその使用方法
|
WO2017201076A1
(en)
*
|
2016-05-16 |
2017-11-23 |
The Board Of Regents Of The University Of Texas System |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
MA45051A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant la relaxine
|
JP2019522047A
(ja)
|
2016-06-13 |
2019-08-08 |
トランスレイト バイオ, インコーポレイテッド |
オルニチントランスカルバミラーゼ欠損症治療のためのメッセンジャーrna療法
|
CN109311809B
(zh)
|
2016-06-24 |
2022-04-08 |
卫材R&D管理有限公司 |
阳离子脂质
|
US11191849B2
(en)
*
|
2016-06-30 |
2021-12-07 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
CA3025812A1
(en)
|
2016-08-19 |
2018-02-22 |
Curevac Ag |
Rna for cancer therapy
|
US11471533B2
(en)
|
2016-09-27 |
2022-10-18 |
Kyowa Kirin Co., Ltd. |
Compound usable as cationic lipid
|
TW201813632A
(zh)
*
|
2016-09-28 |
2018-04-16 |
日商協和醱酵麒麟有限公司 |
含有核酸之脂質奈米粒子
|
US20190314486A1
(en)
|
2016-10-21 |
2019-10-17 |
Merck Sharp & Dohme Corp. |
Influenza hemagglutinin protein vaccines
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMANE CYTOMEGALOVIRUS
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
AU2017356190A1
(en)
|
2016-11-10 |
2019-05-16 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger RNA
|
MA46762A
(fr)
|
2016-11-10 |
2019-09-18 |
Translate Bio Inc |
Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
EP3808380A1
(en)
|
2016-12-08 |
2021-04-21 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
EP3558354A1
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Lassa virus vaccine
|
US11524066B2
(en)
|
2016-12-23 |
2022-12-13 |
CureVac SE |
Henipavirus vaccine
|
DK3565891T3
(da)
|
2017-01-09 |
2023-07-24 |
Whitehead Inst Biomedical Res |
Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer
|
EP3582790A4
(en)
|
2017-02-16 |
2020-11-25 |
ModernaTX, Inc. |
VERY POWERFUL IMMUNOGENIC COMPOSITIONS
|
MA47603A
(fr)
|
2017-02-27 |
2020-01-01 |
Translate Bio Inc |
Nouvel arnm cftr à codons optimisés
|
MA47824A
(fr)
|
2017-03-07 |
2020-01-15 |
Translate Bio Inc |
Administration polyanionique d'acides nucléiques
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
ES2911186T3
(es)
|
2017-03-15 |
2022-05-18 |
Modernatx Inc |
Formas cristalinas de aminolípidos
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
US11464848B2
(en)
|
2017-03-15 |
2022-10-11 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
US20200030432A1
(en)
|
2017-03-17 |
2020-01-30 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
CN110392577A
(zh)
|
2017-03-17 |
2019-10-29 |
库尔维科公司 |
用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂
|
CN110914433A
(zh)
|
2017-03-24 |
2020-03-24 |
库尔维科公司 |
编码crispr相关蛋白质的核酸及其用途
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
US11596679B2
(en)
|
2017-04-27 |
2023-03-07 |
Vanderbilt University |
Hepatitis C virus gene sequences and methods of use therefor
|
CN110799492B
(zh)
|
2017-04-28 |
2023-06-27 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
US11433131B2
(en)
|
2017-05-11 |
2022-09-06 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (SNAs)
|
US11173190B2
(en)
|
2017-05-16 |
2021-11-16 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
|
WO2018222926A1
(en)
|
2017-05-31 |
2018-12-06 |
Ultragenyx Pharmaceutical Inc. |
Therapeutics for glycogen storage disease type iii
|
EP3630200A4
(en)
|
2017-05-31 |
2021-02-24 |
Arcturus Therapeutics, Inc. |
THERAPEUTICS FOR PHENYLKETONURIA
|
WO2018222890A1
(en)
|
2017-05-31 |
2018-12-06 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency rna therapeutics
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
EP3641834B1
(en)
|
2017-06-19 |
2023-10-04 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of friedreich's ataxia
|
US10988754B2
(en)
|
2017-07-04 |
2021-04-27 |
Cure Vac AG |
Nucleic acid molecules
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
WO2019027055A1
(ja)
|
2017-08-04 |
2019-02-07 |
協和発酵キリン株式会社 |
核酸含有脂質ナノ粒子
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
EP3675817A1
(en)
|
2017-08-31 |
2020-07-08 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
EP4219715A3
(en)
|
2017-09-08 |
2023-09-06 |
MiNA Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
EP4233880A3
(en)
|
2017-09-08 |
2023-09-20 |
MiNA Therapeutics Limited |
Hnf4a sarna compositions and methods of use
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
WO2019060442A1
(en)
|
2017-09-19 |
2019-03-28 |
Alnylam Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF TRANSTHYRETIN MEDIATED AMYLOSIS (TTR)
|
CA3073634A1
(en)
|
2017-10-19 |
2019-04-25 |
Curevac Ag |
Novel artificial nucleic acid molecules
|
US11692002B2
(en)
|
2017-11-08 |
2023-07-04 |
CureVac SE |
RNA sequence adaptation
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
WO2019126593A1
(en)
|
2017-12-20 |
2019-06-27 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
BR112020013201A2
(pt)
|
2017-12-27 |
2020-12-01 |
Takeda Pharmaceutical Company Limited |
nanopartícula lipídica, medicamento, métodos para expressar um receptor, para prevenir ou tratar câncer e para produzir um medicamento, uso da nanopartícula lipídica e do imunócito ex vivo, composição, imunócito ex vivo, e, célula ex vivo
|
CA3084657A1
(en)
|
2017-12-27 |
2019-07-04 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
CN111655715A
(zh)
|
2018-01-29 |
2020-09-11 |
默沙东公司 |
稳定化的rsv f蛋白及其用途
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
US20210113483A1
(en)
|
2018-02-02 |
2021-04-22 |
Translate Bio, Inc. |
Cationic Polymers
|
CN111936150A
(zh)
*
|
2018-02-12 |
2020-11-13 |
因特尔纳技术有限公司 |
抗癌微小rna及其脂质制剂
|
WO2019191627A1
(en)
|
2018-03-30 |
2019-10-03 |
Insmed Incorporated |
Methods for continuous manufacture of liposomal drug products
|
EP3773702A2
(en)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
US11566246B2
(en)
|
2018-04-12 |
2023-01-31 |
Mina Therapeutics Limited |
SIRT1-saRNA compositions and methods of use
|
BR112020020933A2
(pt)
|
2018-04-17 |
2021-04-06 |
Curevac Ag |
Moléculas de rna de rsv inovadoras e composições para vacinação
|
EP3793689A1
(en)
|
2018-05-15 |
2021-03-24 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger rna
|
CA3100218A1
(en)
|
2018-05-16 |
2019-11-21 |
Translate Bio, Inc. |
Ribose cationic lipids
|
JP2021525240A
(ja)
|
2018-05-24 |
2021-09-24 |
トランスレイト バイオ, インコーポレイテッド |
チオエステルカチオン性脂質
|
JP2021525725A
(ja)
|
2018-05-30 |
2021-09-27 |
トランスレイト バイオ, インコーポレイテッド |
メッセンジャーrnaワクチンおよびその使用
|
EP3802507A1
(en)
|
2018-05-30 |
2021-04-14 |
Translate Bio, Inc. |
Vitamin cationic lipids
|
CN112424214A
(zh)
|
2018-05-30 |
2021-02-26 |
川斯勒佰尔公司 |
包含甾族部分的阳离子脂质
|
WO2019232097A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
CN112638362A
(zh)
|
2018-07-23 |
2021-04-09 |
川斯勒佰尔公司 |
信使rna的干粉制剂
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
CA3108920A1
(en)
|
2018-08-29 |
2020-03-05 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
EP3849617A1
(en)
|
2018-09-14 |
2021-07-21 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
DK3860561T3
(da)
|
2018-10-01 |
2023-08-07 |
Alnylam Pharmaceuticals Inc |
Bionedbrydelige lipider til levering af aktive stoffer
|
KR20210093232A
(ko)
*
|
2018-10-09 |
2021-07-27 |
더 유니버시티 오브 브리티시 콜롬비아 |
유기용매와 세제가 없는 형질감염 적격 소포를 포함하는 조성물과 시스템 및 관련 방법
|
US20210381006A1
(en)
|
2018-10-18 |
2021-12-09 |
Takeda Pharmaceutical Company Limited |
Method for activation/proliferation of t cells
|
CN112888451A
(zh)
|
2018-10-19 |
2021-06-01 |
川斯勒佰尔公司 |
信使rna的无泵包封
|
EP3876914A2
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
AU2019374871A1
(en)
|
2018-11-09 |
2021-05-27 |
Translate Bio, Inc. |
PEG lipidoid compounds
|
CA3119051A1
(en)
*
|
2018-11-09 |
2020-05-14 |
Arbutus Biopharma Corporation |
Cationic lipids containing silicon
|
CA3117866A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
WO2020097384A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities
|
CA3119449A1
(en)
|
2018-11-12 |
2020-05-22 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
CA3120647A1
(en)
|
2018-11-21 |
2020-05-28 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
AU2019383413A1
(en)
|
2018-11-21 |
2021-05-27 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger RNA
|
HUE064076T2
(hu)
|
2018-12-06 |
2024-02-28 |
Arcturus Therapeutics Inc |
Készítmények és módszerek az ornitin-transzkarbamiláz hiányának kezelésére
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
EP3897702A2
(en)
|
2018-12-21 |
2021-10-27 |
CureVac AG |
Rna for malaria vaccines
|
WO2020146344A1
(en)
|
2019-01-07 |
2020-07-16 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
WO2020146805A1
(en)
|
2019-01-11 |
2020-07-16 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
JP2022519557A
(ja)
*
|
2019-01-31 |
2022-03-24 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の調製方法
|
EP3920950A1
(en)
|
2019-02-08 |
2021-12-15 |
CureVac AG |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
EP3947646A1
(en)
|
2019-04-05 |
2022-02-09 |
Precision BioSciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
EP3956303A1
(en)
|
2019-04-18 |
2022-02-23 |
Translate Bio, Inc. |
Cystine cationic lipids
|
EP3959195B1
(en)
|
2019-04-22 |
2023-11-08 |
Translate Bio, Inc. |
Thioester cationic lipids
|
US20220257724A1
(en)
|
2019-05-03 |
2022-08-18 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
AU2020274758A1
(en)
|
2019-05-14 |
2021-12-23 |
Translate Bio, Inc. |
Improved process of preparing mRNA-loaded lipid nanoparticles
|
KR20220027855A
(ko)
|
2019-05-22 |
2022-03-08 |
매사추세츠 인스티튜트 오브 테크놀로지 |
원형 rna 조성물 및 방법
|
US20220226244A1
(en)
|
2019-05-31 |
2022-07-21 |
Translate Bio, Inc. |
Macrocyclic lipids
|
US20220313813A1
(en)
|
2019-06-18 |
2022-10-06 |
Curevac Ag |
Rotavirus mrna vaccine
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
CN114401942B
(zh)
|
2019-06-21 |
2024-01-26 |
川斯勒佰尔公司 |
三(羟甲基)甲基甘氨酸和柠檬酸脂质
|
AU2020311364A1
(en)
|
2019-07-08 |
2022-02-03 |
Translate Bio, Inc. |
Improved mRNA-loaded lipid nanoparticles and processes of making the same
|
CN114423869A
(zh)
|
2019-07-19 |
2022-04-29 |
旗舰先锋创新Vi有限责任公司 |
重组酶组合物和使用方法
|
EP4003311A1
(en)
|
2019-07-23 |
2022-06-01 |
Translate Bio, Inc. |
Stable compositions of mrna-loaded lipid nanoparticles and processes of making
|
JP2021016370A
(ja)
*
|
2019-07-23 |
2021-02-15 |
株式会社東芝 |
核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
|
US20220323542A1
(en)
|
2019-07-30 |
2022-10-13 |
Translate Bio, Inc. |
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
|
CA3144902A1
(en)
|
2019-08-14 |
2022-01-19 |
Andreas Thess |
Rna combinations and compositions with decreased immunostimulatory properties
|
WO2021055833A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
MX2022003394A
(es)
|
2019-09-20 |
2022-06-22 |
Translate Bio Inc |
Arnm que codifica cftr manipulado.
|
EP4041894A1
(en)
|
2019-09-23 |
2022-08-17 |
Omega Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4a) GENE EXPRESSION
|
CN114391040A
(zh)
|
2019-09-23 |
2022-04-22 |
欧米茄治疗公司 |
用于调节载脂蛋白b(apob)基因表达的组合物和方法
|
JP2022552286A
(ja)
|
2019-10-09 |
2022-12-15 |
トランスレイト バイオ, インコーポレイテッド |
メッセンジャーrnaの組成物、方法および使用
|
EP4048316A1
(en)
|
2019-10-21 |
2022-08-31 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
CA3160739A1
(en)
|
2019-12-04 |
2021-06-10 |
Brian Goodman |
Circular rna compositions and methods
|
EP4076400A1
(en)
|
2019-12-20 |
2022-10-26 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
AU2020407285A1
(en)
|
2019-12-20 |
2022-08-11 |
CureVac SE |
Lipid nanoparticles for delivery of nucleic acids
|
CA3162368A1
(en)
|
2019-12-20 |
2021-06-24 |
Shrirang KARVE |
Rectal delivery of messenger rna
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
IL293571A
(en)
|
2020-02-04 |
2022-08-01 |
Curevac Ag |
Corona virus vaccine
|
AU2021219652A1
(en)
|
2020-02-14 |
2022-08-18 |
Merck Sharp & Dohme Llc |
HPV vaccine
|
AU2021226578A1
(en)
|
2020-02-25 |
2022-10-20 |
Translate Bio, Inc. |
Improved processes of preparing mRNA-loaded lipid nanoparticles
|
AU2021236068A1
(en)
|
2020-03-09 |
2022-10-06 |
Arcturus Therapeutics, Inc. |
Compositions and methods for inducing immune responses
|
JP2023517326A
(ja)
|
2020-03-11 |
2023-04-25 |
オメガ セラピューティクス, インコーポレイテッド |
フォークヘッドボックスp3(foxp3)遺伝子発現をモジュレートするための組成物および方法
|
US20230138409A1
(en)
|
2020-03-24 |
2023-05-04 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
IL296662A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral DNA vectors and their use for expression of Gauche cure
|
WO2021205077A1
(en)
|
2020-04-09 |
2021-10-14 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
CA3177940A1
(en)
|
2020-05-07 |
2021-11-11 |
Anusha DIAS |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
US20230190954A1
(en)
|
2020-05-07 |
2023-06-22 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
US20230181619A1
(en)
|
2020-05-07 |
2023-06-15 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
EP4149556A1
(en)
|
2020-05-14 |
2023-03-22 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
WO2021231901A1
(en)
|
2020-05-15 |
2021-11-18 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
JP2023527309A
(ja)
|
2020-05-19 |
2023-06-28 |
オルナ セラピューティクス インコーポレイテッド |
環状rna組成物及び方法
|
CA3179444A1
(en)
|
2020-05-20 |
2021-11-25 |
Avak Kahvejian |
Immunogenic compositions and uses thereof
|
CN116322760A
(zh)
|
2020-05-20 |
2023-06-23 |
旗舰创业创新第六有限责任公司 |
冠状病毒抗原组合物及其用途
|
US20230203510A1
(en)
|
2020-05-29 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
BR112022024248A2
(pt)
|
2020-05-29 |
2023-10-10 |
CureVac SE |
Vacinas de combinação à base de ácido nucleico
|
US20230203509A1
(en)
|
2020-05-29 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
WO2022006527A1
(en)
|
2020-07-02 |
2022-01-06 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
TW202216190A
(zh)
|
2020-07-08 |
2022-05-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
抗hbv之rna複製子疫苗
|
US20230272432A1
(en)
|
2020-07-27 |
2023-08-31 |
Anjarium Biosciences Ag |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
US20230272052A1
(en)
|
2020-07-31 |
2023-08-31 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
WO2022043551A2
(en)
|
2020-08-31 |
2022-03-03 |
Curevac Ag |
Multivalent nucleic acid based coronavirus vaccines
|
AU2021336976A1
(en)
|
2020-09-03 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
US20230372440A1
(en)
|
2020-10-06 |
2023-11-23 |
Translate Bio, Inc. |
Improved process and formulation of lipid nanoparticles
|
WO2022076547A1
(en)
|
2020-10-07 |
2022-04-14 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
JP2023545128A
(ja)
|
2020-10-12 |
2023-10-26 |
トランスレイト バイオ, インコーポレイテッド |
mRNA搭載脂質ナノ粒子を製造する改善された方法
|
WO2022081548A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing ice-based lipid nanoparticles
|
WO2022099194A1
(en)
|
2020-11-09 |
2022-05-12 |
Translate Bio, Inc. |
Improved compositions for delivery of codon-optimized mrna
|
MX2023006133A
(es)
|
2020-11-25 |
2023-07-18 |
Translate Bio Inc |
Formulaciones estables de nanopartículas de lipídos líquidos.
|
CA3200234A1
(en)
|
2020-11-25 |
2022-06-02 |
Daryl C. Drummond |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
CA3201219A1
(en)
|
2020-12-04 |
2022-06-09 |
Mir Ali |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
JP2024501288A
(ja)
|
2020-12-23 |
2024-01-11 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
修飾tremの組成物及びその使用
|
AU2021412833A1
(en)
|
2020-12-28 |
2023-07-06 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
EP4277929A1
(en)
|
2021-01-14 |
2023-11-22 |
Translate Bio, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
WO2022162027A2
(en)
|
2021-01-27 |
2022-08-04 |
Curevac Ag |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
WO2022204549A1
(en)
|
2021-03-25 |
2022-09-29 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
CA3214137A1
(en)
|
2021-03-26 |
2022-09-29 |
Mina Therapeutics Limited |
Tmem173 sarna compositions and methods of use
|
JP2024511206A
(ja)
|
2021-03-26 |
2024-03-12 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
US20220325287A1
(en)
|
2021-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
CA3215606A1
(en)
|
2021-04-19 |
2022-10-27 |
Shrirang KARVE |
Improved compositions for delivery of mrna
|
KR20240012370A
(ko)
|
2021-04-20 |
2024-01-29 |
안자리움 바이오사이언시스 아게 |
아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법
|
WO2022232286A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
KR20240011714A
(ko)
|
2021-04-27 |
2024-01-26 |
제너레이션 바이오 컴퍼니 |
치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
CA3220358A1
(en)
*
|
2021-05-28 |
2022-12-01 |
Nanovation Therapeutics Inc. |
Kc2-type lipids
|
CN117460542A
(zh)
|
2021-06-11 |
2024-01-26 |
纳米智能生物医学工程有限公司 |
包含用于将寡核苷酸递送至靶细胞内的肽-脂质缀合物的纳米颗粒以及包含其的药物组合物
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
CN117881395A
(zh)
|
2021-07-01 |
2024-04-12 |
翻译生物公司 |
用于递送mRNA的组合物
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
WO2023009547A1
(en)
|
2021-07-26 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
CA3171750A1
(en)
|
2021-07-30 |
2023-02-02 |
Tim SONNTAG |
Mrnas for treatment or prophylaxis of liver diseases
|
CA3227105A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
WO2023010133A2
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
WO2023014677A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
US20230118665A1
(en)
|
2021-08-19 |
2023-04-20 |
Merck Sharp & Dohme Llc |
Novel thermostable lipid nanoparticle and methods of use thereof
|
CN113461577B
(zh)
*
|
2021-09-01 |
2021-12-14 |
中山大学附属第七医院(深圳) |
一种氨基脂质及其应用
|
CN115745942A
(zh)
*
|
2021-09-03 |
2023-03-07 |
广州谷森制药有限公司 |
新型阳离子脂质化合物
|
WO2023031394A1
(en)
|
2021-09-03 |
2023-03-09 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
IL309502A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine
|
CN115772089A
(zh)
*
|
2021-09-07 |
2023-03-10 |
广州谷森制药有限公司 |
新型阳离子脂质化合物
|
EP4271818A1
(en)
|
2021-09-17 |
2023-11-08 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for producing circular polyribonucleotides
|
TW202322826A
(zh)
|
2021-10-18 |
2023-06-16 |
美商旗艦先鋒創新有限責任公司 |
用於純化多核糖核苷酸之組成物及方法
|
WO2023073228A1
(en)
|
2021-10-29 |
2023-05-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2023086893A1
(en)
|
2021-11-10 |
2023-05-19 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
WO2023097003A2
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and their uses
|
WO2023096963A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
WO2023096990A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovation Vi, Llc |
Coronavirus immunogen compositions and their uses
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023115013A1
(en)
|
2021-12-17 |
2023-06-22 |
Flagship Pioneering Innovations Vi, Llc |
Methods for enrichment of circular rna under denaturing conditions
|
WO2023122745A1
(en)
|
2021-12-22 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
WO2023122789A1
(en)
|
2021-12-23 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
WO2023183616A1
(en)
|
2022-03-25 |
2023-09-28 |
Senda Biosciences, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
WO2023190170A1
(ja)
*
|
2022-03-28 |
2023-10-05 |
日油株式会社 |
核酸内封脂質ナノ粒子の製造方法及びこれを含む医薬品組成物の製造方法、並びに、核酸を細胞内又は標的細胞内に導入する方法
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
WO2023214405A1
(en)
|
2022-05-01 |
2023-11-09 |
Yeda Research And Development Co. Ltd. |
Reexpression of hnf4a to alleviate cancer-associated cachexia
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
WO2023220729A2
(en)
|
2022-05-13 |
2023-11-16 |
Flagship Pioneering Innovations Vii, Llc |
Double stranded dna compositions and related methods
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
WO2023240156A1
(en)
|
2022-06-08 |
2023-12-14 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
WO2023250112A1
(en)
|
2022-06-22 |
2023-12-28 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
US20240042021A1
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
US20240067969A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024049979A2
(en)
|
2022-08-31 |
2024-03-07 |
Senda Biosciences, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
CN116270543B
(zh)
*
|
2023-05-19 |
2023-09-26 |
清华大学 |
脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途
|